405 related articles for article (PubMed ID: 36013562)
21. Hyperprolactinemia: pathophysiology and management.
Verhelst J; Abs R
Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
[TBL] [Abstract][Full Text] [Related]
22. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
[TBL] [Abstract][Full Text] [Related]
23. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
24. Giant Prolactinomas.
Shimon I
Neuroendocrinology; 2019; 109(1):51-56. PubMed ID: 30404098
[TBL] [Abstract][Full Text] [Related]
25. Contemporary management of prolactinomas.
Liu JK; Couldwell WT
Neurosurg Focus; 2004 Apr; 16(4):E2. PubMed ID: 15191331
[TBL] [Abstract][Full Text] [Related]
26. Women with prolactinomas presented at the postmenopausal period.
Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
28. Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas.
Hacisahinogullari H; Canturk S; Dogansen S; Yarman S
J Fr Ophtalmol; 2022 May; 45(5):511-518. PubMed ID: 35272874
[TBL] [Abstract][Full Text] [Related]
29. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
[TBL] [Abstract][Full Text] [Related]
30. Prolactinomas and pregnancy.
Bronstein MD
Pituitary; 2005; 8(1):31-8. PubMed ID: 16411066
[TBL] [Abstract][Full Text] [Related]
31. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
Iyer P; Molitch ME
Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
[TBL] [Abstract][Full Text] [Related]
32. Operative treatment of cystic prolactinomas: a retrospective study.
Su W; He K; Yang Y; Xu J; Li X; Tang H; Yang J; Yang L
BMC Endocr Disord; 2023 May; 23(1):99. PubMed ID: 37143054
[TBL] [Abstract][Full Text] [Related]
33. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
34. The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis.
Zou Y; Li D; Gu J; Chen S; Wen X; Dong J; Jiang X
BMC Endocr Disord; 2021 Nov; 21(1):225. PubMed ID: 34774043
[TBL] [Abstract][Full Text] [Related]
35. Surgery as a first-line option for prolactinomas.
Mamelak A
Expert Rev Endocrinol Metab; 2022 Nov; 17(6):485-498. PubMed ID: 36200144
[TBL] [Abstract][Full Text] [Related]
36. Giant prolactinomas: the therapeutic approach.
Moraes AB; Silva CM; Vieira Neto L; Gadelha MR
Clin Endocrinol (Oxf); 2013 Oct; 79(4):447-56. PubMed ID: 23662975
[TBL] [Abstract][Full Text] [Related]
37. Dopamine receptor agonists for treating prolactinomas.
Colao A; di Sarno A; Pivonello R; di Somma C; Lombardi G
Expert Opin Investig Drugs; 2002 Jun; 11(6):787-800. PubMed ID: 12036422
[TBL] [Abstract][Full Text] [Related]
38. [Update on endocrinology: management of prolactinomas during pregnancy].
Cecenarro LA; Estario P; Estario ME; Fux-Otta C
Rev Fac Cien Med Univ Nac Cordoba; 2015; 72(3):170-4. PubMed ID: 26913801
[TBL] [Abstract][Full Text] [Related]
39. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
[TBL] [Abstract][Full Text] [Related]
40. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
